Anemia Management in Peritoneal Dialysis: Perspectives From the Asia Pacific Region

Anemia is an important complication in patients with chronic kidney disease. Peritoneal dialysis (PD) is one of the most common modalities of kidney replacement therapy for patients with end-stage kidney disease. PD is particularly prevalent in the Asian Pacific region. Among the different countries and regions, including mainland China, Hong Kong, Japan, Malaysia, Singapore, South Korea, and Thailand, PD accounts for 2.8% to 74.6% of the dialysis population. In addition, 82% to 96% of the PD populations from these countries and regions are receiving erythropoiesis-stimulating agents (ESAs). Asian Pacific countries and regions follow the latest KDIGO (Kidney Disease: Improving Global Outcomes) guidelines for the initiation of treatment of anemia in PD patients. The types of ESAs commonly used include shorte-racting (epoetin alfa and beta) and longer-acting agents, including darbepoetin alfa or methoxy polyethylene glycol-epoetin beta. The most commonly used ESAs in Mainland China, Malaysia, Singapore, and Thailand are the shorter-acting agents, whereas in Hong Kong, Japan, and South Korea, longer-acting ESAs are most common. Oral iron therapy is still the most commonly used iron supplement. The route and dosage of iron administration in PD patients requires more research studies. With the introduction of oral hypoxia-inducible factor prolyl hydroxylase inhibitors into clinical use, the landscape of treatment of anemia in the PD population in the Asia Pacific region may change in the coming years. (C) 2021 The Authors. Published by Elsevier Inc. on behalf of the National Kidney Foundation, Inc.

Automated summary

Anemia is a significant complication in patients with chronic kidney disease, and peritoneal dialysis is commonly used in the Asian Pacific region. The use of erythropoiesis-stimulating agents varies among countries, with differences in the types of agents used. The introduction of new treatments, such as oral hypoxia-inducible factor prolyl hydroxylase inhibitors, may impact the future landscape of anemia treatment in the PD population in Asia Pacific.